Daily Stock Analysis, HSGX, Histogenics Corp, priceseries

Histogenics Corp. Daily Stock Analysis
Stock Information
Open
0.24
Close
0.24
High
0.25
Low
0.23
Previous Close
0.24
Daily Price Gain
-0.00
YTD High
0.36
YTD High Date
Jun 13, 2019
YTD Low
0.08
YTD Low Date
Jan 2, 2019
YTD Price Change
0.12
YTD Gain
95.12%
52 Week High
1.43
52 Week High Date
Oct 4, 2018
52 Week Low
0.08
52 Week Low Date
Jan 2, 2019
52 Week Price Change
-0.40
52 Week Gain
-62.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 30. 2017
1.57
Feb 3. 2017
1.65
4 Trading Days
5.10%
Link
LONG
Jul 12. 2017
1.77
Jul 27. 2017
1.91
11 Trading Days
7.76%
Link
LONG
Sep 7. 2017
1.89
Sep 19. 2017
2.01
8 Trading Days
6.39%
Link
LONG
Jan 8. 2018
2.24
Jan 18. 2018
2.45
7 Trading Days
9.57%
Link
LONG
Jan 25. 2018
2.67
Jan 26. 2018
2.88
1 Trading Days
7.87%
Link
LONG
Mar 14. 2018
3.04
Mar 15. 2018
3.20
1 Trading Days
5.10%
Link
LONG
May 31. 2018
2.31
Jun 19. 2018
2.74
13 Trading Days
18.69%
Link
Company Information
Stock Symbol
HSGX
Exchange
NasdaqCM
Company URL
http://www.histogenics.com
Company Phone
781-457-7900
CEO
Adam D. Gridley
Headquarters
Massachusetts
Business Address
830 WINTER STREET, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001372299
About

Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.

Description

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.